Safety, effectiveness and tolerance of buprenorphine-naloxone in the treatment of opioid dependence: Results from a nationwide non-interventional study in routine care

Pharmacopsychiatry

Volumn 46, Issue 3, 2013, Pages 94-107

  Apelt, S M ^a,b   Scherbaum, N ^c   Golz J ^d   Backmund, M ^b,e   Soyka, M ^b,f  

^a Certum Consulting Scientific Research   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Praxiszentrum Kaiserdamm   (Germany)

^e PiT Praxis im Tal   (Germany)

^f Privatklinik Meiringen ^*  (Switzerland)

Author keywords

buprenorphine; buprenorphine naloxone; dependence treatment; naloxone; opioids; routine care; safety

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE;

ADULT; ARTICLE; CONNECTIVE TISSUE DISEASE; DRUG EFFICACY; DRUG FATALITY; DRUG MISUSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; GERMANY; HOSPITALIZATION; HUMAN; INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MENTAL HEALTH; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OPIATE ADDICTION; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ADULT; BUPRENORPHINE; DATABASES, BIBLIOGRAPHIC; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OBSERVATION; OPIOID-RELATED DISORDERS; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; QUESTIONNAIRES; SELF-ASSESSMENT;

EID: 84878114289     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0032-1330033     Document Type: Article

References (35)

1. Amato L., Minozzi S., Davoli M. et al. Psychosocial combined with agonist maintenance treatments [Intervention Review]. Cochrane Database of Systematic Reviews: 2011; Issue 10
2. Kamien J. B., Branstetter S. A., Amass L. Buprenorphine-naloxone versus methadone maintenance therapy: a randomized double blind trial with opioid-dependent patients. Heroin Addict Relat Clin Probl: 2008; 10 5 18
3. Hser Y-I, Hoffmann V., Grella C. F. et al. A 33-year follow-up of narcotics addicts. Arch Gen Psychiatry: 2001; 58 503 508
4. Soyka M., Traeder A., Klotsche J. et al. Criminal behavior in opioid-dependent patients before and during maintenance therapy: 6-year follow-up of a nationally representative cohort sample. J Forensic Sci: 2012; 10.1111/j.1556-4029.2012.02234.x
5. Federal Ministry of Health Drug and Addiction Report: 2001
6. NICE NICE guidance. (National Institute for Health and Clinical Excellence) 2012. From http://guidance.nice.org.uk/
7. APA American Psychological Association, 2012. From http://www.apa.org/
8. Kleber H. D., Weiss R. D., Anton R. F. et al. Treatment of patients with substance use disorders, second edition. American Psychiatic Association. Am J Psychiatry: 2006; 163 5 82
9. Soyka M., Kranzler H. R., van den Brink W. et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence. World J Biol Psychiatry: 2011; 12 160 187
10. Wittchen H-U, Apelt S. M., Bühringer G. et al. Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study. Int J Methods Psychiatric Res: 2005; 14 14 28
11. Federal Institute for Drugs and Medical Devices 2011. From www.bfarm.de
12. Comer S. D., Walker E. A., Collins E. C. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychpharmacology: 2005; 181 664 675
13. Connock M., Juarez-Garcia A., Jowett S. et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess: 2007; 11 1 171
14. Mattic R., Ali R., White J. et al. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction: 2003; 98 441 452
15. Johanson C-E, Arfken C. L., di Menza S. et al. Diversion and abuse of buprenorphine: Findings from national surveys. Drug and Alcohol Dependence: 2012; 120 190 195
16. Stroller K. B., Bigelow G. E., Walsh S. L. et al. EC. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology: 2001; 154 230 242
17. ®). Drug and Alcohol Review: 2004; 23 311 317
18. Johnson R. E., McCagh J. C. Buprenorphine and naloxone for heroin dependence. Current Psychiatry Reports: 2000; 2 519 526
19. Fudala P. J., Yu E., Macfadden W. et al. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug and Alcohol Dependence: 1998; 50 1 8
20. Chian C. N., Hawks R. L. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug and Alcohol Dependence: 2003; 70 39 47
21. Mendelson J., Jones R. T. Clinical and pharmacological evaluation of buprenorphine and naloxone combination: why the 4:1 ratio for treatment? Drug and Alcohol Dependence: 2003; 70 29 37
22. Fudala P. J., Williford W. O., Collins J. et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New Engl J Med: 2003; 349 949 958
23. Guy W. Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD National Institute of Mental Health: 1976; 218 222
24. Handelsmann L., Cochrane K. J., Aronson M. J. et al. Two new rating scales for opiate withdrawal. The American Journal of Drug and Alcohol Abuse: 1987; 3 293 308
25. Ware J. E., Scherbourne C. D. The MOS 36-Item Short-Form Health Survey (SF-36). Medical Care: 1992; 30 473 483
26. Derogatis L. R. SCL-90-R. Self-Report Symptom Inventory. In: Scalarum C. I. Internationale Skalen für Psychiatrie. Weinheim Beltz: 1986
27. Franke G. H. Die Symptom-Checkliste von Derogatis - Deutsche Version - (SCL-90-R). Manual. Göttingen Beltz Test GmbH: 1995
28. Stata Corp Stata Statistical Software: Release 9. College Station, TX StataCorp LP: 2005
29. Maintenance and Support Services Organisation (MSSO) MedDRA: Medical Dictionary for Regulatory Activities - Release 11.1. International Federation of Pharmaceutical Manufacturers and Associations (IFPMA),: 2008
30. Wittchen H-U, Apelt S. M., Soyka M. et al. Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients. Drug and Alcohol Dependence: 2008; 95 245 257
31. Schwartz R. P., Kelly S. M., O'Grady K. E. et al. Randomized trial of standard methadone treatment compared to initiating methadone without counselling: 12-month findings. Addiction: 2012; 107 943 952
32. Curcio F., Franco T., Topa M. et al. Buprenorphine/naloxone vs. methadone in opioid dependence: a longitudinal survey. European Review for Medical and Pharmacological Sciences: 2011; 871 874
33. Carrieri M. P., Amass L., Lucas G. M. et al. Buprenorphine use: the international experience. Clin Infect Dis 2006; 43 04 197 215
34. German Federal Ministry of Justice Verordnung über das Verschreiben, die Abgabe und den Nachweis des Verbleibs von Betäubungsmitteln (Betäubungsmittel- Verschreibungsverordnung - BtMVV), 1998 http://www.gesetze-im-internet.de/btmvv-1998/index.html
35. Lieb M., Wittchen H-U, Palm U. et al. Psychiatric comorbidity in substitution treatment of opioid-dependent patients in primary care: Prevalence and impact on clinical features. Heroin Addiction & Related Clinical Problems: 2012; 12 5 16